Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

Abstract

The emergence of chemoresistant disease during chemotherapy with 5-Fluorouracil-based (5-FU-based) regimens is an important factor in the mortality of metastatic CRC (mCRC). The causes of 5-FU resistance are multi-factorial, and besides DNA mismatch repair deficiency (MMR-D), there are no widely accepted criteria for determining which CRC patients are not likely to be responsive to 5-FU-based therapy. Thus, there is a need to systematically understand the mechanistic basis for 5-FU treatment failure and an urgent need to develop new approaches for circumventing the major causes of 5-FU resistance. In this manuscript, we review mechanisms of 5-FU resistance with an emphasis on: (1) altered anabolic metabolism limiting the formation of the primary active metabolite Fluorodeoxyuridylate (5-Fluoro-2'-deoxyuridine-5'-O-monophosphate; FdUMP); (2) elevated expression or activity of the primary enzymatic target thymidylate synthase (TS); and (3) dysregulated programmed cell death as important causes of 5-FU resistance. Importantly, these causes of 5-FU resistance can potentially be overcome through the use of next-generation fluoropyrimidine (FP) polymers (e.g., CF10) that display reduced dependence on anabolic metabolism and more potent TS inhibitory activity.

Keywords

Fluoropyrimidine / 5-FU resistance / colorectal cancer / chemotherapy / precision medicine / thymidylate synthase

References

[1] Dominijanni A.Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.Cancer Drug Resist2018;1:48-58 PMCID:PMC6320232

[2] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[3] González-Senac NM,Macías-Valle A.Colorectal cancer in elderly patients with surgical indication: state of the art, current management, role of frailty and benefits of a geriatric liaison.Int J Environ Res Public Health2021;18:6072 PMCID:PMC8200127

[4] Gmeiner WH.Recent advances in our knowledge of mCRC tumor biology and genetics: a focus on targeted therapy development.Onco Targets Ther2021;14:2121-30 PMCID:PMC8007558

[5] Punt CJ,Vermeulen L.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Nat Rev Clin Oncol2017;14:235-46

[6] Sethy C.5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition.Biomed Pharmacother2021;137:111285

[7] Długosz-Pokorska A,Janecki T.New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line.Mol Biol Rep2019;46:5831-9

[8] Chen P,Xie T.Meta-Analysis of 5-Fluorouracil-Based Chemotherapy Combined With Traditional Chinese Medicines for Colorectal Cancer Treatment.Integr Cancer Ther2019;18:1534735419828824 PMCID:PMC7242800

[9] Luqmani YA.Mechanisms of drug resistance in cancer chemotherapy.Med Princ Pract2005;14 Suppl 1:35-48

[10] Morawska K,Marceau L.5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.Oncotarget2018;9:11559-71 PMCID:PMC5837758

[11] Weckbecker G.Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators.Pharmacol Ther1991;50:367-424

[12] Carreras CW,Cooke R.A C-terminal conformational equilibrium in thymidylate synthase observed by electron paramagnetic resonance spectroscopy.Biochemistry1994;33:2071-7

[13] Wilson PM,Johnston PG,Ladner RD.Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.Nat Rev Clin Oncol2014;11:282-98

[14] Luengo A,Vander Heiden MG.Targeting metabolism for cancer therapy.Cell Chem Biol2017;24:1161-80 PMCID:PMC5744685

[15] Liao ZY,Zhang HL.A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.Cancer Res2005;65:4844-51.

[16] Gmeiner WH,Haber AO.Improved antitumor activity of the Fluoropyrimidine polymer CF10 in preclinical colorectal cancer models through distinct mechanistic and pharmacologic properties.Mol Cancer Ther2021;20:553-63 PMCID:PMC8201368

[17] Haber AO,Mani C.AraC-FdUMP[10] Is a next-generation Fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition.Mol Cancer Res2021;19:565-72 PMCID:PMC9013283

[18] Mani C,Papke CM,Gmeiner WH.Thymineless death by the fluoropyrimidine polymer F10 involves replication fork collapse and is inhanced by Chk1 inhibition.Neoplasia2018;20:1236-45 PMCID:PMC6232621

[19] Miura K,Ishida K.5-fu metabolism in cancer and orally-administrable 5-fu drugs.Cancers (Basel)2010;2:1717-30 PMCID:PMC3837334

[20] Diasio RB.Clinical pharmacology of 5-fluorouracil.Clin Pharmacokinet1989;16:215-37

[21] Longley DB,Johnston PG.5-fluorouracil: mechanisms of action and clinical strategies.Nat Rev Cancer2003;3:330-8

[22] Chalabi-Dchar M,Machon C.A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate.NAR Cancer2021;3:zcab032 PMCID:PMC8364333

[23] Gmeiner WH.Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment.Cancers (Basel)2020;12:1641 PMCID:PMC7352193

[24] Pritchard DM,Potten CS,Hickman JA.Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation.Proc Natl Acad Sci U S A1997;94:1795-9 PMCID:PMC19996

[25] Groeningen CJ, Peters GJ, Leyva A, Laurensse E, Pinedo HM. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.J Natl Cancer Inst1989;81:157-62

[26] Saif MW.Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.Cancer Chemother Pharmacol2016;78:151-6

[27] Saif MW,Purvey S.Pharmacogenetic variants in the DPYD and TYMS genes are clinically significant predictors of fluoropyrimidine toxicity: are we ready for use in our clinical practice.Arch Pharmacol Ther2020;2:6-8

[28] Saif MW,Mehra R,Diasio RB.Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi malignancies: experience of 4-years.Pak J Med Sci2007;23:832-9 PMCID:PMC2563423

[29] Botrel TEA,Paladini L.Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.BMC Cancer2016;16:677 PMCID:PMC4997727

[30] Liu Z,Xu G.Nomogram for predicting overall survival in colorectal cancer with distant metastasis.BMC Gastroenterol2021;21:103 PMCID:PMC7934422

[31] Veenstra CM.Emerging systemic therapies for colorectal cancer.Clin Colon Rectal Surg2018;31:179-91 PMCID:PMC5929883

[32] Shen C,Horn R.Overall survival in phase 3 clinical trials and the surveillance, epidemiology, and end results database in patients with metastatic colorectal cancer, 1986-2016: a systematic review.JAMA Netw Open2022;5:e2213588 PMCID:PMC9131746

[33] André T,Salem ME.Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022.Am Soc Clin Oncol Educ Book2022;42:1-9

[34] Adeleke S,Choy A.Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls.Per Med2022;19:277-86

[35] Aiyer KTS,Ryan NA.Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis.Mod Pathol2022;35:1775-83 PMCID:PMC9708570

[36] Tougeron D,Trouilloud I.Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study.J Natl Cancer Inst2016;108:djv438

[37] Watanabe T,Catalano PJ.Molecular predictors of survival after adjuvant chemotherapy for colon cancer.N Engl J Med2001;344:1196-206 PMCID:PMC3584633

[38] Romano G,Bianco MR.The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.Oncotarget2016;7:22077-91 PMCID:PMC5008345

[39] Jung G,Sánchez A.Current treatments of metastatic colorectal cancer with immune checkpoint inhibitors-2020 update.J Clin Med2020;9:3520 PMCID:PMC7694085

[40] Carethers JM,Fink D.Mismatch repair proficiency and in vitro response to 5-fluorouracil.Gastroenterology1999;117:123-31 PMCID:PMC4343206

[41] Gmeiner WH.Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs.Cancer Drug Resist2019;2:994-1001 PMCID:PMC6953902

[42] Li LS,Veigl M.DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.Br J Pharmacol2009;158:679-92 PMCID:PMC2765589

[43] Gmeiner WH,Palle K.Abstract 2828: MMR status affects efficiency of homologous recombination repair of F10-induced DNA DSBs.Cancer Res 78 (13_Supplement):2828

[44] Wyatt MD.Participation of DNA repair in the response to 5-fluorouracil.Cell Mol Life Sci2009;66:788-99 PMCID:PMC2649968

[45] An Q,Lindahl T.5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity.Cancer Res2007;67:940-5

[46] Bracht K,Liu Y.5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.Br J Cancer2010;103:340-6 PMCID:PMC2920028

[47] Malki A,Gupta I,Vranic S.Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements.Int J Mol Sci2020;22:130 PMCID:PMC7794761

[48] Cheng YW,Bacolod MD.CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer.Clin Cancer Res2008;14:6005-13 PMCID:PMC3268558

[49] Gmeiner WH.Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005;12:191-202.

[50] Yu J,Chen L.Effect of S-1 plus Oxaliplatin compared with Fluorouracil, Leucovorin plus Oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer: a randomized clinical trial.JAMA Netw Open2022;5:e220426 PMCID:PMC8886520

[51] Tong D,Mendis J.Long term real-world outcomes of Trifluridine/Tipiracil in metastatic colorectal cancer-a single UK centre experience.Curr Oncol2021;28:2260-9 PMCID:PMC8293218

[52] Peters GJ,van Groeningen CJ,Meijer S.Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.J Clin Oncol1994;12:2035-42

[53] Noordhuis P,Van der Wilt CL.5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.Ann Oncol2004;15:1025-32

[54] Kasahara M,Nagata T.Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer.Clin Cancer Res2000;6:2707-11

[55] Fang Z,Li C,Gong C.A comprehensive review of the roles of E2F1 in colon cancer.Am J Cancer Res2020;10:757-68 PMCID:PMC7136928

[56] Mannava S,Wheeler LJ.Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.Cell Cycle2008;7:2392-400 PMCID:PMC3744895

[57] Drubin DA,Catlett NL,Wettergren Y.MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer.Journa of Clinical Oncology2021;39:e15512

[58] Varghese V,Harada-Shoji N.FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression.Sci Rep2019;9:1505 PMCID:PMC6365533

[59] Klinhom-On N,Sawanyawisuth K,Mahalapbutr P.FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase.Life Sci2021;286:120072

[60] Ahn JY,Min HY.Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.Oncotarget2015;6:32622-33 PMCID:PMC4741717

[61] Matuszyk J.MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Mol Med2022;28:89 PMCID:PMC9351108

[62] Zhang Y.MicroRNAs are important regulators of drug resistance in colorectal cancer.Biol Chem2017;398:929-38 PMCID:PMC5911396

[63] Ogunwobi OO,Akingboye A.Biomarkers in colorectal cancer: current research and future prospects.Int J Mol Sci2020;21:5311 PMCID:PMC7432436

[64] Johnston PG,Leichman CG.Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.Cancer Res1995;55:1407-12

[65] Copur S,Drake JC,Chu E.Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.Biochem Pharmacol1995;49:1419-26

[66] Salonga D,Johnson M.Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.Clin Cancer Res2000;6:1322-7

[67] Edler D,Ragnhammar P.Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.Clin Cancer Res2000;6:488-92

[68] Edler D,Hallström M.Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.J Clin Oncol2002;20:1721-8

[69] Popat S,Houlston RS.Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.J Clin Oncol2004;22:529-36

[70] Kamynina E.The roles of SUMO in metabolic regulation. In: Wilson VG, editor. SUMO regulation of cellular processes. Cham: Springer International Publishing; 2017. pp. 143-68. PMCID:PMC5471835

[71] Chon J,Field MS.Targeting nuclear thymidylate biosynthesis.Mol Aspects Med2017;53:48-56 PMCID:PMC5253096

[72] Gustavson MD,Tedeschi G,Rimm DL.AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.Arch Pathol Lab Med2008;132:1746-52.

[73] Watson RG,Thorne LB.Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.Eur J Cancer2010;46:3358-64 PMCID:PMC2991554

[74] Wang TL,Romans K.Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.Proc Natl Acad Sci U S A2004;101:3089-94 PMCID:PMC420348

[75] Clark JL,Mittelman A.Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.Cancer Treat Rep1987;71:261-5

[76] Berger SH,Johnson LF.Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.Mol Pharmacol1985;28:461-7

[77] Marsh S,Cassidy J.Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.Int J Oncol2001;19:383-6

[78] Grumetti L,Iannelli F.Epigenetic approaches to overcome Fluoropyrimidines resistance in solid tumors.Cancers (Basel)2022;14:695 PMCID:PMC8833539

[79] Wang YC,Wang ZH.An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.Mol Biol Rep2013;40:4637-44

[80] Mauritz R,Beumer IJ.Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.Clin Colorectal Cancer2009;8:146-54

[81] Peters GJ,Freemantle S.Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.Biochim Biophys Acta2002;1587:194-205

[82] Goff LW,Du L.Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.PLoS One2014;9:e107424 PMCID:PMC4169411

[83] Ntavatzikos A,Patapis P.TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer.World J Gastrointest Oncol2019;11:551-66 PMCID:PMC6657223

[84] Therizols G,Panthu B.Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance.Nat Commun2022;13:173 PMCID:PMC8748862

[85] Very N,Decourcelle A.Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer.Oncogene2022;41:745-56

[86] Zhang N,Xu SJ.5-Fluorouracil: mechanisms of resistance and reversal strategies.Molecules2008;13:1551-69 PMCID:PMC6244944

[87] Matuo R,Escargueil AE.5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line.J Appl Toxicol2009;29:308-16

[88] Humeniuk R,Mishra PJ.Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.Mol Cancer Ther2009;8:1037-44

[89] Diasio RB.Testing for Dihydropyrimidine Dehydrogenase deficiency to individualize 5-Fluorouracil therapy.Cancers (Basel)2022;14:3207 PMCID:PMC9264755

[90] Gmeiner WH.A narrative review of genetic factors affecting fluoropyrimidine toxicity.Precis Cancer Med2021;4:38-38 PMCID:PMC8664072

[91] Lee JJ,Chu E.Therapeutic drug monitoring of 5-fluorouracil.Cancer Chemother Pharmacol2016;78:447-64 PMCID:PMC5204259

[92] Hu S,Yin X,Zhang G.NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer.Biosci Rep2019;39:BSR20190101 PMCID:PMC6522745

[93] Wang D,Yin L,Zhang S.Association of serum levels of deoxyribose 1-phosphate and S-lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: A metabolomics study.Oncol Lett2020;19:2231-42 PMCID:PMC7039117

[94] Peters GJ.Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.Ther Adv Med Oncol2015;7:340-56 PMCID:PMC4622302

[95] Takebayashi Y,Akiba S.Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.J Natl Cancer Inst1996;88:1110-7

[96] Bijnsdorp IV,Jansen EE.Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells.Biochem Pharmacol2010;80:786-92

[97] Matsusaka S,Fukushima M.Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.Chemotherapy2007;53:36-41

[98] Griffith M,Cheung PY.Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer.Pharmacogenomics J2013;13:148-58

[99] Fujii R,Kameoka S.Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.Int J Clin Oncol2003;8:72-8

[100] Fukushima M,Uchida J,Takechi T.Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.Eur J Cancer2001;37:1681-7

[101] Kubota T,Otani Y,Fukushiuma M.Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity.Anticancer Res2002;22:3537-40

[102] Gustavsson M.Evidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast.RNA2008;14:666-74 PMCID:PMC2271368

[103] Okamoto M,Hori M.tRNA modifying enzymes, NSUN2 and METTL1, determine sensitivity to 5-fluorouracil in HeLa cells.PLoS Genet2014;10:e1004639 PMCID:PMC4169382

[104] Xie T,Wang Y.FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.Oncotarget2017;8:8574-89 PMCID:PMC5352423

[105] Pratt S,Kandasamy RA,Perry W 3rd.The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.Mol Cancer Ther2005;4:855-63

[106] Marin JJG,Macias RIR.Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.Cancers (Basel)2022;14:3524 PMCID:PMC9320734

[107] Hientz K,Bhakta-Guha D.The role of p53 in cancer drug resistance and targeted chemotherapy.Oncotarget2017;8:8921-46 PMCID:PMC5352454

[108] Fulda S.Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy.Oncogene2006;25:4798-811

[109] Bunz F,Lengauer C.Requirement for p53 and p21 to sustain G2 arrest after DNA damage.Science1998;282:1497-501

[110] Bunz F,Torrance C.Disruption of p53 in human cancer cells alters the responses to therapeutic agents.J Clin Invest1999;104:263-9 PMCID:PMC408422

[111] Nita ME,Tominaga O.5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins.Br J Cancer1998;78:986-92 PMCID:PMC2063141

[112] Yang CM,Jung WJ.p53 expression confers sensitivity to 5-fluorouracil via distinct chromatin accessibility dynamics in human colorectal cancer.Oncol Lett2021;21:226 PMCID:PMC7856692

[113] Kandioler D,Kappel S.p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG)TP53 mutational status and prediction of benefit from adjuvant 5-Fluorouracil in stage III colon cancer patients.EBioMedicine2015;2:825-30 PMCID:PMC4563117

[114] Backus HH,van Groeningen CJ.Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.Ann Oncol2001;12:779-85

[115] Longley DB,McDermott U.The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites.Clin Cancer Res2004;10:3562-71

[116] Tillman DM,Houghton JA.A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells.Clin Cancer Res1999;5:425-30

[117] Petak I,Tillman DM.Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma.Cell Death Differ2003;10:211-7

[118] Backus HH,van Groeningen CJ.5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.Ann Oncol2001;12:209-16

[119] Xie Q,Li X.The interaction mechanism between autophagy and apoptosis in colon cancer.Transl Oncol2020;13:100871 PMCID:PMC7509232

[120] Li J,Faried A,Kuwano H.Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model.Eur J Cancer2010;46:1900-9

[121] Yao CW,Piao MJ.Reduced autophagy in 5-Fluorouracil resistant colon cancer cells.Biomol Ther (Seoul)2017;25:315-20 PMCID:PMC5424642

[122] Kim EJ,Kang JI.Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells.Oncotarget2018;9:19911-28 PMCID:PMC5929436

[123] Zhang Y,Wang J.MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.Cell Death Dis2015;6:e1845 PMCID:PMC4558495

[124] Chen J,Xiao C.The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy.Oncogene2021;40:3974-88 PMCID:PMC8195740

[125] Bijnsdorp IV,Temmink OH,Kruyt FA.Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.Int J Cancer2010;126:2457-68

[126] de la Cruz-Morcillo MA,Callejas-Valera JL.P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.Oncogene2012;31:1073-85

[127] Gao T,He B.Identification of autophagy related genes in predicting the prognosis and aiding 5- fluorouracil therapy of colorectal cancer.Heliyon2022;8:e09033 PMCID:PMC8904229

[128] Mleczak A,Tooze SA,Chan EY.Regulation of autophagosome formation by Rho kinase.Cell Signal2013;25:1-11

[129] Zheng Z,Li JF.RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells.Oncol Lett2013;5:255-60 PMCID:PMC3525503

[130] Zhang P,Chen HF.Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice.J Exp Clin Cancer Res2017;36:190 PMCID:PMC5741949

[131] Ghosh S,Das U.Curcumin stably interacts with DNA hairpin through minor groove binding and demonstrates enhanced cytotoxicity in combination with FdU nucleotides.Biochim Biophys Acta Gen Subj2018;1862:485-94

[132] Das U,Roy AK,Ghosh S.Hairpin Oligonucleotide can functionalize gold nanorods for in vivo application delivering cytotoxic nucleotides and curcumin: a comprehensive study in combination with near-infrared laser.ACS Omega2020;5:28463-74 PMCID:PMC7658950

[133] Anand P,Sundaram C.Cancer is a preventable disease that requires major lifestyle changes.Pharm Res2008;25:2097-116 PMCID:PMC4969787

[134] Azwar S,Abdullah M,Mohtarrudin N.Recent updates on mechanisms of resistance to 5-Fluorouracil and reversal strategies in colon cancer treatment.Biology (Basel)2021;10:854 PMCID:PMC8466833

[135] Gmeiner WH,Pommier Y.Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.Mol Cancer Ther2010;9:3105-14 PMCID:PMC3059097

[136] Deng J,Lei J,Xiong JP.Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance.Tumour Biol2017;39:1010428317697553

[137] Marjaneh RM,Ferns GA,Aghaee-Bakhtiari SH.The role of microRNAs in 5-FU resistance of colorectal cancer: possible mechanisms.J Cell Physiol2019;234:2306-16

[138] Ghafouri-Fard S,Tondro Anamag F.5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent.Front Oncol2021;11:658636 PMCID:PMC8092118

[139] Touil Y,Corvaisier M.Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.Clin Cancer Res2014;20:837-46 PMCID:PMC4387277

[140] Cho YH,Yoon JS.5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.Nat Commun2020;11:5321 PMCID:PMC7578039

[141] Siebenhüner A,Meisel A,Borner M.Metastatic colorectal carcinoma after second progression and the role of Trifluridine-Tipiracil (TAS-102) in Switzerland.Oncol Res Treat2020;43:237-44

[142] Pardee TS,Jennings-Gee J,Gmeiner WH.Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.Blood2012;119:3561-70 PMCID:PMC3325043

[143] Gmeiner WH.Targeting DNA topoisomerases: past & future.Cancer Drug Resist2021;4:758-61 PMCID:PMC8442622

[144] Pommier Y.Drugging topoisomerases: lessons and challenges.ACS Chem Biol2013;8:82-95 PMCID:PMC3549721